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INTRODUCTION 
 
 High density lipoprotein (HDL) performs a variety of tasks, including its 
prominent role in the defense against atherosclerosis through, primarily, its 
antioxidant effect, as well as by transporting the cholesterol content of peripheral 
cells to the liver (reverse cholesterol transport, RCT). A growing number of 
epidemiological data and clinical studies support the idea that HDL may be the 
next target for the reduction of residual cardiovascular risk in high risk patients 
receiving statin therapy.  
 For over three decades now, HDL-cholesterol (HDL-C) quantitative assays 
have been the primary approach when it comes to assessing HDL. However, a 
number of studies from the recent years have proven that, in addition to circulatory 
HDL-C levels, the qualitative assessment of HDL is even more important since 
HDL-C levels alone do not provide meaningful information about HDL particle 
composition and function. It has also been proven that in treating cardiovascular 
disease, it is rather the improvement of circulatory HDL function than the elevation 
of HDL-C levels that is of key importance.  
Due to HDL's physico-chemical and functional heterogeneity, researchers are 
facing substantial challenges in developing laboratory and clinical methods that are 
more efficient, and more accurate in estimating cardiovascular risk, than HDL-C 
quantitative assays. In spite of the great volume of research, no reliable, widely 
accepted and applied method has been found so far for this purpose.  
 HDL is a small, dense, protein rich lipoprotein with an average size of 8 to 10 
nm and average specific gravity of 1.063 to 1.21 g/mL. HDL particles are complex 
and heterogeneous macromolecules; their protein content (proteome) and lipid 
composition (lipidome) are both diverse, resulting in inhomogeneity in terms of 
size, density, structure, and function, thus they can be classified into sub-fractions, 
which are in a continuous process of transforming into one another. A substantial 
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portion of proteome constituent proteins are those required for lipid transport or 
lipoprotein structural unity (apolipoproteins), but there are also a number of other 
proteins active in HDL's anti-inflammatory, anti-atherogenic and pleiotropic effect. 
In terms of structure and function, apolipoprotein AI (apoAI) is the most important 
protein of HDL. Key functions of apoAI include stabilizing the structure of the 
HDL particle and the activation of lecithin–cholesterol acyltransferase (LCAT). In 
addition to these, most of HDL's anti-atherogenic and anti-inflammatory potential, 
– i.e. neutralization of lipid hydroperoxides, ATP-binding cassette protein A1 
(ABCA1) mediated cholesterol efflux, as well as interaction with the ATP-binding 
cassette protein G1 (ABCG1) transporter and scavenger receptor class B type I 
(SR-BI) – is also linked to apoAI.  
 Through its antioxidant effect, HDL can protect low density lipoprotein 
(LDL) from oxidative damage caused by free radicals through the inhibition of the 
formation of oxidized lipids with pro-inflammatory effects – mainly lipid 
hydroperoxides but also, to a partial extent, short-chain oxidized phospholipids. 
HDL receives lipid hydroperoxides from the oxidized LDL, with HDL's protein 
and lipid components themselves undergoing modification in the process. HDL, 
while transporting lipid hydroperoxides to SR-BI receptors of the liver, reduces 
and thus inactivates them as well. A prominent role in this is played by apoAI's 
methionine side chains. Nonetheless, the antioxidant effect of HDL is contributed 
to by other apolipoproteins as well as enzymes related to HDL. Several studies 
have proven that the distribution of apolipoprotein variants and antioxidant 
enzymes differs across HDL sub-fractions. 
One of the most important enzymes involved in the antioxidant effect HDL is 
paraoxonase 1 (PON1). Its effects include arylesterase, phosphodiesterase 
(paraoxonase) and lactonase activities. The arylesterase activity of PON1 strongly 
correlates with the quantity of the circulatory PON1 protein and is an indicator of 
the antioxidant effect of the latter, while paraoxonase activity is significantly 
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influenced by inter-individual differences caused by genetic polymorphism. It has 
long been known that, with the assistance of PON1, HDL can inhibit LDL 
oxidation by hydrolyzing oxidized phospholipids; furthermore, it is hypothesized 
that PON1 can increase the free radical reduction capability of 
monocytes/macrophages, enhances the removal of cholesterol coming from 
macrophages, and can enhance HDL's capability to stop LDL oxidation by 
macrophages. In addition to these, PON1 may modify the activity of 
myeloperoxidase (MPO) which, in turn, is an inhibitor of PON1. A major 
discovery of the last few years was that HDL, MPO, and PON1 form a three-
element unit, in which it is not only that MPO inhibits PON1's activity, but PON1 
also partially reduces MPO's activity. Prospective studies show convincing 
evidence in relation to the role played by PON1 in cardiovascular diseases. It has 
been proven beyond doubt that reduced PON1 activity is a risk factor of vascular 
diseases.  
HDL function is also exposed to negative interference by a number of 
molecules. A prominent one of these is MPO which, by virtue of its bactericide 
effect, constitutes an important component of congenital immunity. Several studies 
also investigate MPO's role played in the pathomechanism of atherosclerosis: by 
oxidizing LDL, MPO facilitates LDL uptake by macrophages, thus it contributes to 
the formation of foam cells. MPO also oxidatively modifies apoAI, resulting in 
damage to HDL binding to ABCA1, which in turn leads to a disruption of ABCA1-
dependent reverse cholesterol transport, and inhibits HDL's anti-inflammatory and 
anti-apoptotic abilities. In addition, MPO directly damages the function of HDL-
bound PON1, as well as ABCG1-dependent cholesterol transport. Consequently, 
elevated MPO levels have been implicated in intensified atherosclerosis; there are 
even a number of studies evaluating MPO as a cardiovascular marker. 
It has recently been proven that another enzyme, matrix metalloproteinase 9 
(MMP-9), is also capable of forming a complex with HDL, especially HDL2, and 
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thus potentially contributes to the formation of dysfunctional HDL. Members of 
the zinc-dependent endopeptidase family, MMP enzymes play a key role in the 
breakdown of extracellular matrix, thereby contributing to the generation and 
destabilization of vulnerable atherosclerotic plaques, and thus the onset of 
cardiovascular events. Tissue inhibitors of metalloproteinase (TIMP) regulate 
MMP activity by binding to the enzyme molecules. Several studies prove that 
patients with cardiovascular disease have elevated TIMP-1 levels; it has also been 
proven that TIMP-1 is an independent predictor of cardiovascular mortality. It is 
hypothesized that such elevated TIMP-1 levels may reflect a compensatory 
response to increased MMP activity.  
Another highly important function of HDL is the delivery of excess cellular 
cholesterol from peripheral tissues to the liver via the process of reverse cholesterol 
transport; such cholesterol then either gets secreted into the bile and passes with 
feces or ends up in the adrenal glands, testes or ovaries for the purpose of steroid 
hormone synthesis. Through this process, HDL is able to counterbalance the 
processes leading to atherosclerotic plaque formation and development. HDL sub-
fractions vary in the extent to which they can facilitate cholesterol efflux.  
During cholesterol efflux, which is the first step of RCT, free cholesterol is 
released from cells. This is produced by passive and active processes acting in a 
parallel fashion. Transport protein mediated active processes play a substantially 
greater role in reverse cholesterol transport. Three major transporters have so far 
been identified: ABCA1, ABCG1, and SR-BI. The most important function is 
served by ABCA1, which transports, in addition to non-esterified cholesterol, 
phospholipids – mainly, phosphatidylcholine – to lipid-free or lipid-poor apoAI, 
thus contributing to the formation of pre-beta-HDL as well. While ABCA1 
transports cholesterol primarily to lipid-poor apoAI, ABCG1 and SR-BI do so 
mainly to mature HDL. During reverse cholesterol transport, HDL itself also 
undergoes structural and functional changes. As a first step, lipid-poor apoAI joins 
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together with plasma membrane derived phospholipids and non-esterified 
cholesterol to form pre-beta-HDL. Upon cholesterol uptake, small pre-beta1-HDL 
molecules turn into larger, but still discoidal, pre-beta2-HDL particles; these in 
turn evolve, by cholesterol esterification and further apoAI uptake, into spherical 
alpha3-HDL, then alpha2-HDL. A number of enzymes work to ensure the smooth 
functioning of reverse cholesterol transport (cholesteryl ester transfer protein 
(CETP), LCAT, phospholipid transfer protein (PLTP), hepatic lipase (HL), 
endothelial lipase (EL)). At the end of the process residual lipid-free or lipid-poor 
apoAI particles then either contribute again to HDL formation, or get filtered 
through renal glomeruli, which takes place via endocytosis mediated by cubilin and 
megalin receptors found in the proximal tubules.  
The key role of apoAI in reverse cholesterol transport is highlighted by the 
fact that cells found in the intima of atherosclerotic arteries secrete a variety of 
proteases that may modify HDL, partly by the proteolysis of apoAI found in pre-
beta-HDL, leading to the inability of apoAI to bind to ABCA1, which may result in 
a reduction of apoAI's potential to facilitate ABCA1 mediated cholesterol efflux 
and HDL biogenesis. Some studies even show that the proteolysis of apoAI may 
damage its potential to facilitate ABCG1 mediated cholesterol efflux. It is also 
widely known that one of the targets of nitration and chlorination catalyzed by 
MPO is apoAI; it is hypothesized that oxidative damage to apoAI thus limits apoAI 
release from HDL in a lipid-free form, which is detrimental to its recycling – 
another mechanism contributing to the reduction of ABCA1 mediated cholesterol 
reflux. 
 Beyond these, HDL is known to affect cell survival, proliferation and 
migration, and to have an antithrombotic effect; HDL may contribute to endothelial 
repair processes and can directly stimulate the nitric oxide (NO) production, as 
well as playing an important role in the body's immunological potential. 
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 The composition and function of HDL may also be endogenously affected by 
genetic factors, and exogenously by the presence and activity of 
enzymes/molecules binding to it to form a functional unit (e.g. PON1, MPO); 
selected diseases and medicinal therapy can likewise be influential. 
More than 40 genes that affect HDL cholesterol levels have been identified to 
this day. Located in the brush border of jejunal epithelial cells, the Niemann–
Pick C1-like 1 (NPC1L1) protein came to the forefront of attention when it had 
turned out that it is this protein to which ezetimibe binds to inhibit cholesterol 
absorption. Upon sequencing the NPC1L1 gene, it became known that in carriers 
of certain NPC1L1 variants, cholesterol absorption rates are significantly lower 
than in non-carriers of those variants. Cholesterol enters the epithelial cells of the 
small intestine through the NPC1L1 protein, during which process NPC1L1 
determines the quantity of cholesterol ending up in circulation. Cholesterol is 
esterified in the intestinal epithelial cells and, via the ABCA1 transporter located at 
the basolateral margin of the cell, enters the lymphatic system, which in turn 
transports it to the liver. In a situation of low cellular cholesterol, NPC1L1 gets 
expressed in the membrane; and when the cells become saturated with cholesterol, 
the receptor becomes internalized into endosomes. To this date, in excess of 140 
single nucleotide polymorphisms (SNP) and five insertions/deletions have been 
identified within the NPC1L1 gene. Several of these SNPs affect therapeutic 
responses to statin (hydroxy-methyl-glutaryl-coenzyme A reductase inhibitor) or 
statin-ezetimibe combined treatment. It has recently been proven that c.-133A>G 
has a significant effect on NPC1L1's promoter activity; the mutation significantly 
modified the lipid lowering effect of statin therapy during pravastatin treatment. 
Up until now, a substantial proportion of studies have researched the effect of 
ezetimibe in combination with statins only; the effects of individual SNPs on the 
response to ezetimibe monotherapy have not yet been studied. 
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In several pathologies (such as coronary heart disease, type 2 diabetes, 
metabolic syndrome, systemic lupus erythematosus, rheumatoid arthritis, Crohn's 
disease, antiphospholipid syndrome, psoriasis, chronic renal disease, and selected 
environmental pollutions), the presence of a so called dysfunctional HDL has been 
established, a variety with notable pro-oxidative and pro-inflammatory 
characteristics. In dysfunctional HDL, a reduced level of atheroprotective, and an 
elevated level of proatherogenic molecules are present; this is accompanied by a 
higher oxidized fatty acid and malonaldehyde content, with – partly after 
chlorination or nitration caused by MPO – oxidative modification of apoAI, and 
detectable changes to PON1 activity. Dysfunctional HDL is incapable of 
preventing LDL oxidation; reverse cholesterol transport is compromised, adhesion 
of white blood cells to activated endothelial cells is reduced, endothelial nitrogen 
monoxide (NO) synthesis induction is cut, endothelial repair functions are 
damaged.  
Based on the reverse association between HDL-C and cardiovascular events, 
boosting HDL-C levels might appear to be an attractive therapeutic target, which 
explains the great number of medicines being developed and studied. Still, a 
number of clinical trials in coronary disease patients failed to achieve substantial 
cardiovascular risk reduction in spite of an elevation in HDL-C levels. A 
substantial proportion of patients on statin therapy develop some level of 
intolerance to the medication used. Although the frequency of side effects caused 
by statins is no greater than that with other drugs, the importance of the issue has 
grown due to the high number of patients on statin treatment. In the era preceding 
the wide availability of proprotein convertase subtilisin/kexin type 9 (PCSK9) 
inhibitors, cardiovascular risk reduction in statin intolerant patients remains some 
of a challenge. The cardiovascular risk reduction effect of ezetimibe is moderate in 
comparison to that of statins; however, in statin intolerant patients, ezetimibe is one 
of the most frequently recommended therapies amongst currently available 
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medications, thus ezetimibe monotherapy is in widespread use in such patients. 
Ezetimibe is a highly tolerable medicine; on average, it delivers 15 to 20% in LDL-
cholesterol (LDL-C) reduction and about 3% in HDL-C elevation. Ezetimibe 
decreases the amount of cholesterol en route to the liver; the number of LDL 
receptors increases, which leads to reduced LDL-C levels through intensifying the 
catabolism of LDL. It has also been proven that ezetimibe also enhances several 
constituent processes of reverse cholesterol transport.  
There is a growing body of evidence indicating that the measurement of a 
single HDL component (such as cholesterol content) is insufficient to estimate the 
cardioprotective function of HDL. HDL-C level alone may be indicative of the 
number of particles in question, but it fails to inform about the subgroup with the 
greatest involvement in the protection against cardiovascular disease. Therefore, 
isolated measurement of HDL-C levels (i.e., cholesterol content carried by HDL) 
does not appear to be the most reliable predictor of HDL function. A number of 
experimental and clinical data also suggest the possibility that the composition of 
the HDL particle may change in selected diseases or upon certain therapies, with 
such changes not necessarily being reflected by HDL-C levels. Based on all these, 
it is evident that future studies will need to investigate the relationship between 
HDL structure and function, leading to more accurate ways to estimate 
cardiovascular risks and therapeutic effects; these findings may also even offer 
new treatment options. 
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OBJECTIVES 
 
1. Our aim was to examine the effect of 3, 6 and 12 months of  of 10 mg 
daily ezetimibe monotherapy on lipid, hsCRP and creatinine-kinase levels 
in statin-intolerant, hyperlipidemic patients. 
2. Our additional objective was to study the genotype distrtibution of SNP 
c.-133A>G at the NPC1L1 gene.  
3. Furthermore, we aimed to evaluate the efficacy of SNP c.-133A>G at the 
NPC1L1 gene on lipid levels in the same study population 
4. In the second part of our studies we measured and compared the levels of 
PON1, MPO and other two biomarkers involved in the atherosclerotic 
process (MMP-9 and TIMP-1) in overweight hyperlipidemic, lipid-
lowering therapy-naive patients with and without vascular complications. 
5.  Our additional objective was the investigation of association of MPO - 
PON1, MPO – MMP-9 and MPO – TIMP1 in the same study population. 
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PATIENTS AND METHODS 
Enrollment of statin intolerant patients 
One hundred and one (69 females, 32 males), Fredrickson type IIa and IIb 
hyperlipidemic patients with previously diagnosed statin induced adverse effects 
were enrolled. Patients were recruited from our lipidology outpatient clinic at 
Institute of Medicine, University of Debrecen. The mean age of studied patients 
was 61.23±9.87 years, BMI of our patients was 28.18±4,29 kg/m2. In 42 cases 
statin-induced myopathy (myalgia with or without creatine-kinase (CK) elevation), 
in 28 cases statininduced liver enzyme elevation (hepatopathy), in 15 cases statin-
induced severe gastrointestinal symptoms were proved. Sixteen patients had more 
than one statin-induced symptom: two patients had myopathy, hepatopathy and 
gastrointestinal symptoms, seven had myopathy and hepatopathy, five had 
myopathy and gastrointestinal symptoms, and two patients had hepatopathy and 
gastrointestinal symptoms. Patients with alcoholism, drug dependence, 
malignancy, pregnancy or lactation, as well as patients on anticoagulant or lipid-
lowering therapy were excluded. After 6 weeks on the National Cholesterol 
Education Program step 1 diet, patients received 10 mg/day ezetimibe (Ezetrol) for 
12 months. Informed consent was obtained from all patients after explaining the 
nature and the purpose of the study. The Ethics Committee of the University of 
Debrecen, the National Institute of Pharmacy approved the study. The study is 
registered by the European Clinical Trials Database (EudraCT number 2009–
017732–40). 
Enrollment of overweight, therapy naive patients 
In the second part of our study 167 (89 females and 78 males) overweight 
adult Caucasian patients with Fredrickson type IIa and IIb hyperlipidemia were 
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enrolled. The mean age of studied patients was 50.0 (41-61) years, BMI of our 
patients was 28.49±5.56 kg/m2.Participants were recruited from our lipidology 
outpatient clinic at Institute of Medicine, University of Debrecen. Overweight was 
defined according to the subjects’ body mass index (BMI ≥ 25 kg/m2).  
Physical examination and carotid ultrasound were performed regularly. Other 
imaging techniques (Doppler ultrasound, echocardiography and computer 
tomography) were performed in case of complaints or abnormal physical and 
electrocardiography (ECG) examinations. We determined the presence of 
hypertension, type 2 diabetes mellitus and smoking habits in all patients. 
Hypertension was defined as the recurrent use of antihypertensive drugs or systolic 
blood pressure ≥ 140 mmHg, diastolic BP ≥ 90 mmHg. The diagnosis of type 2 
diabetes mellitus was made by recurrent use of antidiabetic drugs or insulin or a 
fasting blood glucose level ≥ 7 mmol/l. Smoking was defined as previous (in the 
last 10 years and longer-than-six-months-lasting) and current smoking habits. 
Study subjects were divided into two gender-matched subgroups as patients with 
pre-existing vascular complications (VC) and patients without vascular 
complications (NVC). (Patients with vascular complications: mean age: 
60.49±10.05; 22 females and 19 males; BMI: 29.34± 3.94 kg/m2. Patients without 
vascular complications: mean age: 46.93± 12.40; 67 females and 59 males; BMI: 
28.18±6.00 kg/m2). Vascular complications were defined as known ischemic heart 
disease (myocardial infarction or coronary sclerosis), ischemic cerebrovascular 
disease (ischemic stroke, transient ischemic attack, carotid artery 
stenosis/occlusion) and peripheral arterial disease.  Vascular complications were 
established by the history data of patients or the results of imaging techniques.  
Patients were divided into the “patients with vascular complications” group if they 
had at least one complication. At the time of the enrollment, patients were free of 
acute complaints. Exclusion criteria included (at least 6 weeks) previous and 
ongoing lipid lowering therapy, autoimmune disease, chronic inflammatory states, 
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active liver or endocrine disease including type 1 diabetes mellitus, malignancy 
and end-stage kidney failure. The study was carried out according to the 
Declaration of Helsinki and informed consent was obtained from all patients after 
approval of the local ethics committee. 
 
Sample collection and laboratory measurement of statin intolerant patients 
At baseline and after 3, 6 and 12 months of treatment with ezetimibe, after 12 
h of fasting, a 10-ml venous blood sample was taken between 07.30 and 08.00 a.m. 
Serum cholesterol, triglyceride, HDL-C, LDL-C, apoAI, apolipoprotein B (apoB), 
high-sensitivity C reactive protein (hsCRP) levels and creatinine-kinase (CK) 
activity were determined from fresh sera with standard laboratory measurements in 
the Institute of Laboratory Medicine, University of Debrecen. 
 NPC1L1 genotype analysis 
Genomic DNA was isolated from EDTA (ethylenediaminetetraacetic acid) or 
citrate-anticoagulated blood in the the Institute of Laboratory Medicine, University 
of Debrecen. The presence of the c.-133A>G polymorphism (rs17655652) was 
tested by enzyme digestion of PCR amplified products.  
Statistical analyses of the results in statin intolerant patients 
Statistica forWindows 6 and IBM Statistical Package for the Social Sciences 
(SPSS) Statistics Version 19 computer softwares were used for statistical analysis. 
Normality of distribution was tested by the Kolmogorov-Smirnov test. In case of 
normal distribution the differences between parameters were analyzed with one-
way analysis of variance (ANOVA), followed by post hoc comparisons using the 
Newman-Keuls test. In cases of non-normal distributions the differences were 
compared with Kruskal-Wallis and Mann-Whitney U tests.  A value of P < 0.05 
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was considered to be statistically significant. The genotype-dependence of changes 
was analyzed by Welch’s robust test. The data of persons with various genotypes 
and alleles were compared using the chi-square and Fisher’s exact test. 
Sample collection and laboratory measurement of overweight, therapy naive 
patients 
Venous blood samples were taken between 08:00 - 10:00 a.m. after an 
overnight fast and sera were prepared immediately. Routine laboratory analyses 
(hsCRP, triglyceride, total cholesterol, LDL-C, HDL-C, ApoAI, ApoB, lipoprotein 
(a) (Lp(a)), hemoglobin A1C (HbA1C), uric acid and ultrasensitive thyroid-
stimulating hormone (sTSH) levels) were determined with standard laboratory 
measurements in the Institute of Laboratory Medicine, University of Debrecen. 
The sera for MPO, MMP-9, TIMP-1 and PON1 paraoxonase and arylesterase 
measurements were kept at -70°C until analysis, samples were used within 2 
months. Serum concentrations of MPO, MMP-9 and TIMP-1 were measured by 
sandwich enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems 
Europe Ltd., Abington, England) according to the recommendations of the 
manufacturer. 
 
Paraoxonase-1 measurements 
PON1 paraoxonase and arylestarse activity was analyzed by 
spectrophotometrically. Paraoxonase activity was assayed on a microtiter plate, 
utilizing paraoxon (O,O-diethyl-O-p-nitrophenyl-phosphate, Sigma) as a substrat 
and the generation of 4-nitrophenol was measured on a microtiter plate at 405 nm. 
PON1 paraoxonase activity was expressed in U/l, where 1 unit equals 1 µmol of 
substrate hydrolyzed per minute. Arylesterase activity was analyzed by the 
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hydrolysis of phenylacetate (Sigma) at 270 nm. Arylesterase activity was 
expressed as units per liter of serum. 1 unit of arylesterase activity is defined as 1 
μmol phenylacetate hydrolyzed per minute. 
PON1 (Q192R) phenotype was calculated by the dual substrate method. The 
hydrolysis of paraoxon is faster by the R allele than by the Q allele. In contrast, 
both R and Q alleles had similar arylesterase activity. The ratio of the hydrolysis of 
paraoxon in the presence of 1 mol/l NaCl (salt-stimulated paraoxonase) to the 
hydrolysis of phenylacetate was used to assign individuals to one of the three 
possible PON1 phenotypes: low activity, intermediate activity and high activity.  
 
Statistical analyses of the results in overweight, therapy naive patients 
Statistical analysis was performed by SAS™ for Windows™ 8.2 computer 
software (SAS Institute Inc., Cary, NC, USA). Normality of distribution was tested 
with Kolmogorov-Smirnov test. Comparisons between groups with normal 
distribution were performed by a Student t-test whereas comparisons between non-
normally distributed parameters were performed with Mann-Whitney U-test. 
Correlations between the investigated parameters were assessed by Pearson's 
correlation analysis; the above mentioned non-normally distributed parameters 
were transformed logarithmically to correct their skewed distributions. Multiple 
regression analysis (backward-stepwise method) was performed to determine 
variables that best predicted MPO levels in the whole patient group as well as in 
the VC and NVC subgroups. We used two sided p-values; p<0.05 was accepted as 
the level of significance. 
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RESULTS 
The effect of c.-133A>G polymorphism in Niemann–Pick C1-Like 1 gene on the 
efficiency of ezetimibe monotherapy 
After 3 months of ezetimibe treatment the total cholesterol (p<0.001), LDL-C 
(p<0.001) and hsCRP (p<0.01) levels significantly decreased, while the other 
studied parameters (triglyceride, HDL-C, ApoB, ApoAI and CK levels) did not 
change significantly in the whole study population. Six months of treatment 
significantly decreased the total cholesterol (p<0.001), LDL-C (p<0.001), hsCRP 
(p<0.01), triglyceride (p<0.01), and ApoB (p<0.01) levels compared to the initial 
results. After 12 months of treatment we found significantly decreased total 
cholesterol (p<0.001), LDL-C (p<0.001), triglyceride (p<0.05) and ApoB levels 
(p<0.01). The HDL-C and apoAI levels dis not change significantly after 12 
months of ezetimibe monotherapy in the whole study population. 
In the studied population the NPC1L1 c.-133A>G genotype distribution was 
as follows: 57.42 % were AA, 34.65% were AG and 7.92% were GG genotype. 
Because of the low ratio of GG patients we divided the study population into two 
groups: AA (G non-carriers) and AG+GG (G carriers). There were no significant 
differences in initial lipid levels between AA and AG+GG patients. We could not 
find significant differences in age, body mass index (BMI) and waist 
circumference between the two groups. 
Plasma levels of ApoA1 did not change significantly after 3, 6 and 12 months 
of ezetimibe treatment (1.96; 3.39 and 2.74%, respectively) in AA patients. 
However, significant elevation in ApoA1 levels has been found after treatment in 
AG+GG patients (9.15; 8.54 and 13.58%, respectively). The effect of NPC1L1 -
133A >G on the efficacy of ezetimibe treatment on ApoA1 level was significant (p 
< 0.05). HDL-C levels remained unchanged in both groups, and there was no 
significant difference between the two groups. 
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Comparing the two groups we could not find any significant difference in the 
efficacy of treatment with ezetimibe on other plasma lipid parameters after 3, 6 or 
12 months. After 3 and 12 months of ezetimibe treatment LDL-C and total 
cholesterol levels significantly decreased both in the AA and in the AG+GG 
groups (p<0.05). The ApoB level decreased significantly only in the AA group 
after 6 months and 12 months therapy, but there was no significant difference 
between the two groups. 
The tolerability of ezetimibe was excellent. No patient had to discontinue the 
drug due to side effects. CK level did not significantly change after 12 months of 
ezetimibe monotherapy as well. 
The association between the paraoxonase-1 activity, myeloperoxidase level and 
the levels of other vascular biomarkers (MMP-9 and TIMP-1) in overweight, 
therapy naive patients 
Compared to the patients without vascular complications (NVC subgroup), 
patients with vascular complications (VC subgroup) were significantly older 
(NVC: 46.93±12.40 years vs. VC: 60.49±10.05, p<0.001), while there were no 
significant differences in BMI or waist circumference between the two subgroups. 
Measuring the laboratory parameters, we did not find significant differences in 
fasting glucose or HbA1C levels between the subgroups. The VC subgroup had a 
more atherogenic lipid profile with significantly higher total cholesterol (p<0.01), 
LDL-C and TG levels (p<0.05); however, HDL-C, apoA1, apoB and Lp(a) levels 
did not differ significantly between the VC and NVC subgroups. Also, there was 
no significant difference in the hsCRP concentrations. 
PON1 Q192R phenotype distribution and allelic frequencies were also 
evaluated. The PON1 phenotype distribution was as follows: in the whole patient 
group 80 % (n=134) were AA, 20 % (n=33) were AB phenotype, and there were 
no patients with BB phenotype. The phenotype distribution (AA-AB) was 83% 
19 
 
(n=104), 17% (n=22) in NVC patients and 73% (n=30), 27% (n=11) in VC 
subgroup, respectively. The allelic frequencies followed the Hardy-Weinberg 
equilibrium and no significant differences were found between the subgroups. 
There was no significant difference in MMP-9 levels between the two 
investigated subgroups; however, MPO and TIMP-1 levels were significantly 
higher (MPO: 728 (367.25-1177.90) mg/ml vs. 315.9 (176.05-687.40) mg/ml; 
p<0.001; and TIMP-1: 172.7 (157.7-197.7) ng/ml vs. 152.6 (129.3-172.3) ng/ml; 
p<0.0001) and the MMP-9/TIMP-1 ratio (3.02 (1.95-4.22) vs. 3.50 (2.34-5.20), 
p<0.0001) was significantly lower in VC patients when compared to NVC 
subjects. We did not find significant differences in PON1 activities between the 
two subgroups, in contrast, tha MPO/PON1 ratio was significantly higher in VC 
patients than in NVC patients (p<0,05). 
MPO level showed a significant negative univariate correlation with PON1 
arylesterase activity in the whole patient group (r=0.42, p<0.0001), as well as in 
both subgroups (VC: r=0.44, p=0.01; NVC: r=0.39, p<0.0001). Investigating the 
relationship between MPO levels and PON1 paraoxonase activity, we did not find 
any significant correlations in the patient groups. MPO concentration showed a 
significant positive univariate correlation with MMP-9 level (r=0.37, p<0.0001F) 
in the whole patient group as well as in the NVC subgroup (r=0.42, p<0.0001). 
Although not reaching the level of significance, perhaps due to the low number of 
individuals in this subgroup, MPO levels tended to correlate positively with MMP-
9 levels in VC patients (r=0.29, p=0.07). MPO and TIMP-1 levels showed a 
significant positive correlation in the whole patient group (r=0.42, p<0.0001) as 
well as in the subgroups (NVC: r=0.41, p<0.0001; VC: r=0.33, p<0.05). Also, 
PON1 arylesterase activity displayed a significant negative correlation with TIMP-
1 levels both in the whole patient group (r=-0.24, p<0.01) and in the NVC 
subgroup (r=-0.26, p<0.01). 
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We performed multiple regression analysis with MPO levels as the dependent 
variable. PON1 arylesterase activity, MMP-9 and TIMP-1 levels were proven to be 
independent predictors of MPO levels both in the whole patient group 
betegcsoportban (PON1 arylesterase activity: ß=-0.350; MMP-9: ß=0.315; TIMP-
1: ß=0.292; p<0.0001) and NVC subgroup (PON1 arylesterase activity: ß=-0.330; 
MMP-9: ß=0.351; TIMP-1: ß=0.262; p<0.0001). In contrast, only PON1 
arylesterase activity was proven to be an independent predictor of MPO levels in 
the VC subgroup (ß=-0.570, p<0.05). 
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DISCUSSION 
In the first part of our examinations the effect of c.-133A>G polymorphism in 
Niemann–Pick C1-Like 1 gene on lipid levels especially on HDL-C and apoAI 
levels was studied in statin intolerant, hyperlipidemic patients with ezetimibe 
monotherapy. 
In former studies different HDL-C raising effect of ezetimibe has been 
shown. Some researchers found that ezetimibe could increase the HDL-C level 
significantly, while in a study of healthy men there were no difference in HDL 
levels between the placebo group and the ezetimibe monotherapy group. 
Nevertheless, the effect of NPC1L1 polymorphisms on the HDL-C response to 
ezetimibe monotherapy has not been studied yet.  
In our study we could not find a significant difference in the response to 
ezetimibe on HDL-C between the patients carrying NPC1L1 -133 AA and in 
AG+GG patients. Contrarily, in AA patients plasma levels of ApoA1 did not 
decrease significantly after 3, 6 and 12 months of ezetimibe treatment. While, a 
significant elevation in ApoA1 levels has been found after treatment in AG+GG 
patients. Based on these results we reported firstly that NPC1L1 c.-133A>G SNP 
influenced the ApoA1 response to ezetimibe monotherapy, therefore, might alter 
the effect of ezetimibe on the structure and function of the HDL particles. 
In our study we could confirm that ezetimibe monotherapy improved the lipid 
parameters in statin intolerant hyperlipidaemic patients. Ezetimibe monotherapy 
significantly reduced the total cholesterol (-11.70 %), LDL-C (-8.52 %) and the 
triglyceride levels (-3.70 %), while the HDL-C levels (1.45 %) did not increase 
significantly. A previous meta-analysis found that ezetimibe monotherapy 
decreased LDL-C level by -18.58 %, and reduces total cholesterol and triglyceride 
concentration by -13.46 % and -8.06% compared to placebo, respectively. 
HDL-cholesterol level was also found to significantly increase by 3%. In our 
study the reduced cholesterol altering effect of ezetimibe can be – at least partially 
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- explained by our study population. Other studies have investigated the effects of 
ezetimibe in patients with diverse lipoprotein abnormalities (e.g. type 2 diabetes 
and mixed hyperlipidemia), while we enrolled a specific statin-intolerant 
hyperlipidemic population. In addition, in our patients the distribution of 
Apolipoprotein E allele could be different from the distribution of former study 
populations.  
In former trials ezetimibe monotherapy decreased hsCRP level compared 
with placebo, but the differences had generally not been found to be statistically 
significant as well. We found significantly reduced hsCRP level after 3 and 6 
months of ezetimibe monotherapy, but we could not find significant difference 
after 12 months in all patients. The studied NPC1L1 polymorphism did not alter 
the effect of ezetimibe on CRP level significantly.  
There are only few data about the genotype distribution of NPC1L1 c.-
133A>G SNP. In a previous study genotype distribution of the c.-133A>G 
NPC1L1 polymorphism was similar to our patients. In this study among the 
autosomal dominant hypercholesterolemic group (n=271), 48% of patients were 
AA allele carriers, 46 % and 6% were AG and GG allele carriers, respectively. 
While in the control group (n=272) the genotype distribution was as follows: 58% 
were AA, 35% were AG and 7% were GG genotype. 
The maximum cholesterol-lowering effect of ezetimibe evolved the first 2 
weeks, and then it remained the same. Therefore most trials have followed the 
ezetimibe efficacy only for 12 weeks. Though in short-term (12 weeks) trials the 
safety profile of ezetimibe monotherapy seems to be like placebo’s, there has been 
limited information about the long-term safety of ezetimibe. In our study a one-
year ezetimibe treatment was examined, and it was well tolerated. No patient had 
to discontinue the drug due to side effects. We did not experience severe side 
effects. CK level did not significantly change after 12 months of ezetimibe 
monotherapy as well. 
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In the second part of our examinations the relationship between two enzymes 
associated with HDL (PON1 activities and MPO concentration) and the level of 
two biomarkers involved in the atherosclerotic process (MMP-9 and TIMP-1) was 
investigated in statin-naive overweight hyperlipidemic patients. The tight 
relationship between MPO – MMP-9 – TIMP-1 levels, MPO level – PON1 
activity, as well as the chronic inflammation that is characteristic for 
atherosclerosis, obesity and cardiovascular diseases have been well known for 
several years, although their associations have not been completely clarified yet. 
This is the first study in which PON1 activity, MPO, MMP-9 and TIMP-1 levels 
were examined simultaneously 
In this examination individuals with vascular complications had significantly 
higher MPO levels compared to those without any complications, suggesting 
increased oxidative stress and a more atherogenic milieu in these subjects. 
We demonstrated firstly the significant positive associations between MPO 
and MMP-9 levels and between MPO and TIMP-1 levels in statin-naive 
overweight hyperlipidemic patients. These correlations were observed in 
subgroups with and without vascular complications as well. Although patients 
without vascular complications were free of manifest atherosclerotic signs, one 
might conclude that early-stage asymptomatic atherosclerosis might already be 
present in them due the obesity-related low-grade chronic inflammation; that 
atherogenetic process, however, is not diagnosable in the premature stage in these 
younger individuals. 
In our statin-naive, hyperlipidemic patients MPO concentrations showed 
significant negative correlations with PON1 arylesterase activities in the whole 
patient group as well as in both subgroups. Our results correspond with the data of 
researches in patients with type 2 diabetes mellitus or coronary artery disease. 
Based on multiple regression analysis, PON1 arylesterase activity was proven to be 
an independent predictor of MPO concentration in the whole patient population as 
24 
 
well as in both subgroups. Our in vivo results correspond with the in vitro data of 
Huang et al. These data indicate that MPO and PON1 mutually inhibit each other’s 
effect. 
In our patients the MPO/PON1 ratio was significantly higher in the VC 
subgroup compared to the NVC group, consequently the examination of this 
parameter may be related to the severity of atherosclerosis. This finding supports 
the results of a research published in 2014. Moreover, this study also raised the 
possibility that the MPO/PON1 ratio could be a potential indicator for 
dysfunctional HDL therefore could be a beneficial marker for secondary 
prevention of cardiovascular disease. 
We did not find any significant correlation between PON1 paraoxonase 
activities and MPO levels, which may have been due to the high inter-individual 
variability of paraoxonase activity. We also did not detect any significant 
difference in PON1 activities (arylesterase or paraoxonase) comparing the two 
subgroups. 
PON1 arylesterase activity, MMP-9 as well as TIMP-1 levels proved to be 
significant predictors of MPO levels both in the whole patient group and in the 
NVC subgroup; however, the correlation between MPO and PON1 seems to be the 
strongest one since only PON1 arylesterase activity was proven to be independent 
predictor of MPO levels in patients with vascular complications. The correlations 
found in our overweight, hyperlipidemic individuals suggest cumulative and 
synergistic atherogenic effects in which elevated levels of MPO contribute to the 
development of the vascular events by direct enhancement of oxidative stress and 
by indirect impairment of anti-atherogenic PON1 function. Besides the significant 
correlations of MPO with MMP-9 and TIMP-1 levels, PON1 arylesterase activity 
also showed a significant negative correlation with TIMP-1 levels, which suggests 
that PON1 might also be influenced by inflammatory factors causing enzyme 
inactivation.  
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These findings support that MPO-PON1-HDL is a complex system. Therefore, 
investigating HDL and its related biomarkers (PON1 and MPO) may be a potential 
marker for the presence of dysfunctional HDL and parallel examination of these 
parameters – supplemented with other biomarkers involved in the atherosclerotic 
process - may add further information on the severity of the atherosclerotic process 
in overweight patients. Parallel investigation of these parameters may be useful for 
selecting high-risk cardiovascular patients which may allow earlier treatment and 
may improve treatment or can help to follow-up the effectiveness of therapy. 
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SUMMARY 
Recently, several researches demonstrated the significant antiatherosclerotic 
effect of HDL. There is a growing body of evidence indicating that the 
measurement of a single HDL component (such as cholesterol content) is 
insufficient to estimate the cardioprotective function of HDL. Based on these 
results it is obvious that examinations dealing with the association between the 
structure and function of HDL are needed.  
Numerous genes associated with HDL have a so-called endogenous effect on 
the level and structure of HDL. Furthermore, enzymes/molecules which form a 
functional complex with HDL can affect exogenously the function of HDL as well.  
First, we aimed to examine the effect of SNP c.-133A>G at the NPC1L1 gene 
on lipid levels and on the efficacy of 3, 6 and 12 months of 10 mg daily ezetimibe 
monotherapy in hyperlipidemic patients. Furthermore, we also examined PON1 
activities, MPO concentration and the level of two biomarkers involved in the 
atherosclerotic process, MMP-9 and TIMP-1, in overweight hyperlipidemic, lipid-
lowering therapy-naive patients with and without vascular complications. 
In patients with ezetimibe monotherapy HDL-C levels remained unchanged 
in both AA and AG+GG group, and there was no significant difference between 
the two groups. Interestingly, plasma levels of apoA1 did not change significantly 
after 3, 6 and 12 months of ezetimibe treatment in AA patients. However, 
significant elevation in ApoA1 levels has been found after treatment in AG+GG 
patients. The effect of NPC1L1 c.-133A>G on the efficacy of ezetimibe treatment 
on ApoA1 level was significant (p < 0.05).  
In our overweight hyperlipidemic, lipid-lowering therapy-naive patients there 
was no significant difference in HDL-C levels between patients with and without 
vascular complaints. MPO level showed a significant negative univariate 
correlation with PON1 arylesterase activity in the whole patient group as well as in 
both subgroups, while MPO concentration showed a significant positive univariate 
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correlation with MMP-9 and TIMP-1 levels as well. MPO/PON1 ratio was 
significantly higher in patients with vascular complications than in patients without 
any complications. We performed multiple regression analysis and PON1 
arylesterase activity, MMP-9 and TIMP-1 levels were proven to be independent 
predictors of MPO levels, moreover, the correlation between MPO and PON1 
seems to be the strongest one. 
In our studies we did not find significant differences in HDL-C levels. 
However, NPC1L1 c.-133A>G SNP influenced the ApoA1 response to ezetimibe 
monotherapy, therefore, might alter endogenously the effect of ezetimibe on the 
structure and function of the HDL particles. Moreover, parallel investigation of 
HDL and its related biomarkers, PON1 and MPO, by modification of HDL 
function, was a more accurate indicator of the severity of atherosclerosis in 
overweight patients, and it might be a possible indicator for dysfunctional HDL. 
Our results confirm that the examination of factors affecting the quality of HDL 
can assist the estimation of the cardioprotective role of HDL and therefore may be 
more important than the measurement of HDL-C level alone.  
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